Jennifer L. Payne, M.D.
Dr. Payne is Associate Professor of Psychiatry and Director, Women's Mood Disorders Center, Johns Hopkins School of Medicine, Baltimore, MD.
Within the past 12 months, Dr. Payne has been a consultant to AstraZeneca and Pfizer.
Off-label uses of medications will be discussed throughout this Cyberounds.
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- List two known risks to the baby of not treating a major depressive episode during pregnancy
- Identify two potential risks to the baby of the use of serotonin reuptake inhibitors during the third trimester
- Apply the risk factors that should be taken into account when deciding on a clinical plan for the management of major depression during pregnancy.